Developer docs
API playgroundTry for free, no card

Search company profiles

Bioscript Group

Full company profile

uuid0009x3b

Namestring
Bioscript Group
Legal namestring
Bioscript Group
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Bioscript Group is a privately held UK-headquartered medical communications and strategy consultancy serving pharmaceutical, biotechnology, and broader life sciences organisations. Founded in 2005 in Macclesfield and backed by Sovereign Capital Partners since March 2021 under a 5-year investment plan, the company has built an integrated offering across five core service lines: Medical Communications, Regulatory Writing, Market Access Consulting (via subsidiary Valid Insight), Data Insights (via subsidiary Bioscript Data Insights), and Strategic Planning. Services span publication planning, scientific storytelling, clinical study reports, BLA/MAA submissions, health economics and value communication, systematic literature reviews, and consensus-driven evidence generation, with deep domain specialisation in oncology and rare diseases. Geographic operations cover the UK (Macclesfield headquarters and London) and the United States (Princeton, New Jersey, via Bioscript Science LLC).

The company's technology layer centres on Synapse by Bioscript Data Insights, an AI-augmented connected-intelligence platform launched in full in November 2025 that integrates congress intelligence, KOL mapping, publication trends, evidence generation, predictive publication planning, and MSL insights mining. Underpinning capabilities include natural language processing, predictive analytics, recommendation engines, knowledge retrieval across PubMed and clinical trial registries, and an agentic AI foundation tailored to regulatory writing. The model combines automated AI with experienced scientific writers described as a high proportion of Senior and Principal Writers and Regulatory Writing Directors with 15+ years of industry experience.

Bioscript monetises primarily through project-based professional services engagements with enterprise pharma and biotech clients, with consultative direct sales as the principal go-to-market motion. The portfolio has expanded via acquisitions of Fortis, Meridian, and Valid Insight (2021), Enzyme Communications (April 2025), and Triducive Partners (May 2026). The company has refreshed its brand in October 2025 around a 'Crystal Clear Consultancy' positioning and reports headcount of 101-250 employees across the UK and US, with named industry awards including EcoVadis, Cyber Essentials Plus, Great Place to Work, and British Data Awards 2026.

Short descriptiontext

Bioscript Group is a UK-headquartered, PE-backed medical communications and strategy consultancy serving pharmaceutical, biotechnology, and life sciences clients with integrated services spanning medical communications, regulatory writing, market access, data insights, and strategic planning, supported by the AI-augmented Synapse intelligence platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMacclesfield, United Kingdom
HQ citystring
Macclesfield
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical communications consulting, regulatory writing services, market access consulting, healthcare data analytics, pharmaceutical strategy consulting
Industry3 codes
PRIMARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code3 codes
  • Other Scientific and Technical Consulting Services54169
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Management Consulting Services8742
Product category
Medical Communications & Strategy Consulting
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Professional Services - Medical Communications
TypeProfessional Services
Description

Bioscript Group provides integrated medical communications services including scientific storytelling, strategic planning, medical content creation, publication planning and dissemination, and medical education support. Revenue is generated through project-based consulting engagements with pharmaceutical and life sciences clients.

bioscriptgroup.com
2Regulatory Writing Services
TypeProfessional Services
Description

The company delivers regulatory writing services for clinical study reports, common technical document modules, and regulatory submissions including BLA/MAA packages. Services include writing, quality control, and project management support.

bioscriptgroup.com
3Market Access Consulting
TypeProfessional Services
Description

Valid Insight, part of Bioscript Group, provides market access consulting including health economics, value communication, negotiation training, and payer strategy development. These are delivered as strategic consulting engagements.

bioscriptgroup.com
4Data Insights and Analytics
TypeProfessional Services
Description

Bioscript Data Insights (BDI) provides analytics services, systematic literature reviews, real-world evidence analysis, and AI-enabled insight generation. Services are delivered through project engagements and may include platform/software access as part of the service offering.

bioscriptgroup.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Synapse
Description

AI-augmented connected intelligence platform designed to help scientific and strategic teams access insights across congress data, publications, KOL activity, and competitive intelligence.

bioscriptgroup.com
+2 more records
Core offering1 text field

Bioscript Group is an integrated medical communications and strategy consultancy serving pharmaceutical, biotechnology, and life sciences organisations. It delivers five core service lines — Medical Communications, Regulatory Writing, Market Access Consulting, Data Insights, and Strategic Planning — supported by its proprietary AI-augmented Synapse intelligence platform that connects congress data, KOL activity, publications, and competitive insights. Services span scientific storytelling, clinical study reports and BLA/MAA submissions, health economics and value communication, evidence synthesis, and consensus-driven insight generation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 75% reduction in evidence synthesis timelines
+7 more records
Product overview1 text field

Bioscript Group is an integrated medical communications and strategy consultancy serving life sciences organizations. The offering operates as a platform-plus-specialist model centered on five core services: Medical Communications, Regulatory Writing, Market Access Consulting (via Valid Insight), Data Insights (BDI), and Strategic Planning. These are supported by the AI-augmented Synapse intelligence platform which connects congress data, KOL activity, publications, and competitive intelligence. The portfolio has been expanded through acquisitions of Enzyme Communications (2025) for scientific storytelling capabilities and Triducive Partners (2026) for consensus-driven evidence generation. Geographic presence includes UK (Macclesfield headquarters, London office) and US (Princeton, NJ). The company also publishes industry benchmark reports including The State of AI in Regulatory Writing 2026.

Product and service6 records
1Medical Communications
CategoryMedical Communications
Description

Scientific storytelling and strategic communication services that transform complex science into clear, engaging content for pharmaceutical and biotech clients across oncology, rare diseases, and other therapy areas. Covers publication planning, medical education, stakeholder engagement, and scientific narrative development.

2Regulatory Writing
CategoryRegulatory Writing
Description

Expert regulatory document creation and submission support for pharmaceutical clients, including clinical study reports (CSRs), common technical document (CTD) modules, BLA/MAA submissions, and NDA documentation. Delivers accurate, compliant documents tailored to streamline regulatory pathways, supported by an agentic AI platform.

3Market Access Consulting (Valid Insight)
CategoryMarket Access Consulting
Description

Market access consulting delivered through the Valid Insight brand, covering health economics, value communication, payer engagement, and negotiation training. Helps shape strategies that reflect science, evidence, and reimbursement realities to secure favourable positioning with payers and decision-makers.

4Data Insights (Bioscript Data Insights / BDI)
CategoryData Insights & Analytics
Description

Specialist healthcare data, AI, and evidence generation services delivered through the Bioscript Data Insights (BDI) team, combining data science, information science, public health expertise, and AI-enabled analytics for evidence synthesis, systematic literature reviews, and data-driven decision-making.

5Strategic Planning
CategoryStrategic Planning
Description

Cross-functional strategic planning and insight services supporting early-stage and ongoing product planning, including hypothesis-driven research, integrated planning, evidence generation strategy, expert engagement, and communication strategy development for pharmaceutical clients.

6Synapse by Bioscript Data Insights
CategoryAI Intelligence Platform
Description

AI-augmented connected intelligence platform that unifies congress intelligence, KOL activity, publication trends, and competitive insights into a single interface. Includes congress intelligence with 48-hour post-event delivery, KOL recommender and predictive behaviour mapping, evidence generation, predictive publication planning, and MSL insights mining for medical affairs teams.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Medical communications agency within the Inizio healthcare services platform, offering publication planning, medical affairs, and scientific communications to pharma clients globally.

TypeDirect peer
Description

Medical communications and scientific visualization agency serving pharma and biotech with publications, medical affairs, and creative scientific content. Comparable mid-scale medcomms peer.

TypeDirect peer
Description

Independent medical communications and value demonstration consultancy with deep expertise in publication planning, HEOR, and patient engagement. Direct competitor with overlapping service portfolio.

TypeDirect peer
Description

Independent medical communications agency offering medical writing, scientific content, and digital solutions to pharma and biotech. Comparable boutique-to-mid-scale peer serving the same customer types.

TypeDirect peer
Description

Global medical communications and technology-enabled solutions provider serving pharma clients across publication planning, medical affairs, and real-world evidence. Direct competitor in the same product category and customer base as Bioscript.

TypeDirect peer
Description

Medical communications and consulting agency serving pharma and biotech across commercial, medical, and clinical disciplines. Comparable integrated services model targeting similar customers.

TypeBroad incumbent
Description

Large global CRO with adjacent regulatory writing, medical communications, and market access capabilities within its broader clinical and commercialization portfolio. Not a specialist peer but competes for the same pharma spend.

TypeDirect peer
Description

Medical communications network providing scientific communications, medical affairs, and patient engagement services to pharma. Directly comparable offering and customer profile.

TypeBroad incumbent
Description

World's largest CRO with broad life sciences services including regulatory, HEOR, and real-world evidence capabilities. Competes with Bioscript at the high end of the regulatory writing and evidence generation market.

TypeOthers
Description

Recently acquired by Bioscript (May 2026); included here as a useful comparator for consensus-driven evidence generation methodology before integration. Listed because the company still operates as an identifiable specialist.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability11 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioscript Group

Medical Communications & Strategy Consultingbioscriptgroup.com

Bioscript Group is a UK-headquartered, PE-backed medical communications and strategy consultancy serving pharmaceutical, biotechnology, and life sciences clients with integrated services spanning medical communications, regulatory writing, market access, data insights, and strategic planning, supported by the AI-augmented Synapse intelligence platform.

What Bioscript Group does

Bioscript Group is a privately held UK-headquartered medical communications and strategy consultancy serving pharmaceutical, biotechnology, and broader life sciences organisations. Founded in 2005 in Macclesfield and backed by Sovereign Capital Partners since March 2021 under a 5-year investment plan, the company has built an integrated offering across five core service lines: Medical Communications, Regulatory Writing, Market Access Consulting (via subsidiary Valid Insight), Data Insights (via subsidiary Bioscript Data Insights), and Strategic Planning. Services span publication planning, scientific storytelling, clinical study reports, BLA/MAA submissions, health economics and value communication, systematic literature reviews, and consensus-driven evidence generation, with deep domain specialisation in oncology and rare diseases. Geographic operations cover the UK (Macclesfield headquarters and London) and the United States (Princeton, New Jersey, via Bioscript Science LLC).

The company's technology layer centres on Synapse by Bioscript Data Insights, an AI-augmented connected-intelligence platform launched in full in November 2025 that integrates congress intelligence, KOL mapping, publication trends, evidence generation, predictive publication planning, and MSL insights mining. Underpinning capabilities include natural language processing, predictive analytics, recommendation engines, knowledge retrieval across PubMed and clinical trial registries, and an agentic AI foundation tailored to regulatory writing. The model combines automated AI with experienced scientific writers described as a high proportion of Senior and Principal Writers and Regulatory Writing Directors with 15+ years of industry experience.

Bioscript monetises primarily through project-based professional services engagements with enterprise pharma and biotech clients, with consultative direct sales as the principal go-to-market motion. The portfolio has expanded via acquisitions of Fortis, Meridian, and Valid Insight (2021), Enzyme Communications (April 2025), and Triducive Partners (May 2026). The company has refreshed its brand in October 2025 around a 'Crystal Clear Consultancy' positioning and reports headcount of 101-250 employees across the UK and US, with named industry awards including EcoVadis, Cyber Essentials Plus, Great Place to Work, and British Data Awards 2026.

Bioscript Group firmographics

Firmographics
Name
Bioscript Group
Legal name
Bioscript Group
Website
https://bioscriptgroup.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
Bioscript Group is a UK-headquartered, PE-backed medical communications and strategy consultancy serving pharmaceutical, biotechnology, and life sciences clients with integrated services spanning medical communications, regulatory writing, market access, data insights, and strategic planning, supported by the AI-augmented Synapse intelligence platform.
Ownership category
akta.pro rank

Bioscript Group industry classification

Industry
Product category
Medical Communications & Strategy Consulting
NAICS
Other Scientific and Technical Consulting Services (54169), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Medical communications consulting
  • Regulatory writing services
  • Market access consulting
  • Healthcare data analytics
  • Pharmaceutical strategy consulting

Where Bioscript Group is headquartered

Location

Headquarters

HQ city
Macclesfield
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Bioscript Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Professional Services - Medical Communications: Bioscript Group provides integrated medical communications services including scientific storytelling, strategic planning, medical content creation, publication planning and dissemination, and medical education support. Revenue is generated through project-based consulting engagements with pharmaceutical and life sciences clients.
  2. Regulatory Writing Services: The company delivers regulatory writing services for clinical study reports, common technical document modules, and regulatory submissions including BLA/MAA packages. Services include writing, quality control, and project management support.
  3. Market Access Consulting: Valid Insight, part of Bioscript Group, provides market access consulting including health economics, value communication, negotiation training, and payer strategy development. These are delivered as strategic consulting engagements.
  4. Data Insights and Analytics: Bioscript Data Insights (BDI) provides analytics services, systematic literature reviews, real-world evidence analysis, and AI-enabled insight generation. Services are delivered through project engagements and may include platform/software access as part of the service offering.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Bioscript Group product offering

Product offering

Core offering

Bioscript Group is an integrated medical communications and strategy consultancy serving pharmaceutical, biotechnology, and life sciences organisations. It delivers five core service lines — Medical Communications, Regulatory Writing, Market Access Consulting, Data Insights, and Strategic Planning — supported by its proprietary AI-augmented Synapse intelligence platform that connects congress data, KOL activity, publications, and competitive insights. Services span scientific storytelling, clinical study reports and BLA/MAA submissions, health economics and value communication, evidence synthesis, and consensus-driven insight generation.

Product overview

Bioscript Group is an integrated medical communications and strategy consultancy serving life sciences organizations. The offering operates as a platform-plus-specialist model centered on five core services: Medical Communications, Regulatory Writing, Market Access Consulting (via Valid Insight), Data Insights (BDI), and Strategic Planning. These are supported by the AI-augmented Synapse intelligence platform which connects congress data, KOL activity, publications, and competitive intelligence. The portfolio has been expanded through acquisitions of Enzyme Communications (2025) for scientific storytelling capabilities and Triducive Partners (2026) for consensus-driven evidence generation. Geographic presence includes UK (Macclesfield headquarters, London office) and US (Princeton, NJ). The company also publishes industry benchmark reports including The State of AI in Regulatory Writing 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • Synapse: AI-augmented connected intelligence platform designed to help scientific and strategic teams access insights across congress data, publications, KOL activity, and competitive intelligence.
  • Bioscript Data Insights (BDI)
  • Valid Insight

Products and services

  • Medical Communications Scientific storytelling and strategic communication services that transform complex science into clear, engaging content for pharmaceutical and biotech clients across oncology, rare diseases, and other therapy areas. Covers publication planning, medical education, stakeholder engagement, and scientific narrative development.
  • Regulatory Writing Expert regulatory document creation and submission support for pharmaceutical clients, including clinical study reports (CSRs), common technical document (CTD) modules, BLA/MAA submissions, and NDA documentation. Delivers accurate, compliant documents tailored to streamline regulatory pathways, supported by an agentic AI platform.
  • Market Access Consulting (Valid Insight) Market access consulting delivered through the Valid Insight brand, covering health economics, value communication, payer engagement, and negotiation training. Helps shape strategies that reflect science, evidence, and reimbursement realities to secure favourable positioning with payers and decision-makers.
  • Data Insights (Bioscript Data Insights / BDI) Specialist healthcare data, AI, and evidence generation services delivered through the Bioscript Data Insights (BDI) team, combining data science, information science, public health expertise, and AI-enabled analytics for evidence synthesis, systematic literature reviews, and data-driven decision-making.
  • Strategic Planning Cross-functional strategic planning and insight services supporting early-stage and ongoing product planning, including hypothesis-driven research, integrated planning, evidence generation strategy, expert engagement, and communication strategy development for pharmaceutical clients.
  • Synapse by Bioscript Data Insights AI-augmented connected intelligence platform that unifies congress intelligence, KOL activity, publication trends, and competitive insights into a single interface. Includes congress intelligence with 48-hour post-event delivery, KOL recommender and predictive behaviour mapping, evidence generation, predictive publication planning, and MSL insights mining for medical affairs teams.

Quantifiable outcome

  • 75% reduction in evidence synthesis timelines
  • +7 more outcomes

Companies that use Bioscript Group

Customer profile

Segments3 records

Ideal customer profiles1 record

Bioscript Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature8 records

Bioscript Group partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Bioscript Group competitors and assessment

Company assessment

Direct peers

  • Ashfield MedComms (part of Inizio): Medical communications agency within the Inizio healthcare services platform, offering publication planning, medical affairs, and scientific communications to pharma clients globally.
  • Complete HealthVizion: Medical communications and scientific visualization agency serving pharma and biotech with publications, medical affairs, and creative scientific content. Comparable mid-scale medcomms peer.
  • Oxford PharmaGenesis: Independent medical communications and value demonstration consultancy with deep expertise in publication planning, HEOR, and patient engagement. Direct competitor with overlapping service portfolio.
  • AMICULUM: Independent medical communications agency offering medical writing, scientific content, and digital solutions to pharma and biotech. Comparable boutique-to-mid-scale peer serving the same customer types.
  • Envision Pharma Group: Global medical communications and technology-enabled solutions provider serving pharma clients across publication planning, medical affairs, and real-world evidence. Direct competitor in the same product category and customer base as Bioscript.
  • Fishawack Health: Medical communications and consulting agency serving pharma and biotech across commercial, medical, and clinical disciplines. Comparable integrated services model targeting similar customers.
  • Nucleus Global: Medical communications network providing scientific communications, medical affairs, and patient engagement services to pharma. Directly comparable offering and customer profile.

Broad incumbents

  • Parexel International: Large global CRO with adjacent regulatory writing, medical communications, and market access capabilities within its broader clinical and commercialization portfolio. Not a specialist peer but competes for the same pharma spend.
  • IQVIA: World's largest CRO with broad life sciences services including regulatory, HEOR, and real-world evidence capabilities. Competes with Bioscript at the high end of the regulatory writing and evidence generation market.

Others

  • Triducive Partners Limited: Recently acquired by Bioscript (May 2026); included here as a useful comparator for consensus-driven evidence generation methodology before integration. Listed because the company still operates as an identifiable specialist.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Bioscript Group social profiles

Digital presence

Bioscript Group compliance and trust

Trust signal

Compliance4 records

Bioscript Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioscript Group leadership team

Management profile

Number of profiles

Profiles13 records

Bioscript Group subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Bioscript Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioscript Group M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioscript Group

What does Bioscript Group do?

Bioscript Group is an integrated medical communications and strategy consultancy serving pharmaceutical, biotechnology, and life sciences organisations. It delivers five core service lines — Medical Communications, Regulatory Writing, Market Access Consulting, Data Insights, and Strategic Planning — supported by its proprietary AI-augmented Synapse intelligence platform that connects congress data, KOL activity, publications, and competitive insights. Services span scientific storytelling, clinical study reports and BLA/MAA submissions, health economics and value communication, evidence synthesis, and consensus-driven insight generation.

Is Bioscript Group a public or private company?

Bioscript Group is a private company. It is classified as private equity controlled and is currently operating.

When was Bioscript Group founded?

Bioscript Group was founded in 2005. It employs 101 to 250 people.

Where is Bioscript Group based?

Bioscript Group is headquartered in Macclesfield, United Kingdom, in the Europe region.

How does Bioscript Group make money?

Four revenue lines are on record. Professional Services - Medical Communications are the primary driver. The others are regulatory Writing Services, market Access Consulting and data Insights and Analytics.

Who are Bioscript Group's main competitors?

Direct peers on record are Ashfield MedComms (part of Inizio), Complete HealthVizion, Oxford PharmaGenesis, AMICULUM, Envision Pharma Group, Fishawack Health and Nucleus Global. Broad incumbents are Parexel International and IQVIA. Triducive Partners Limited is listed as an others.

Does Bioscript Group have an API?

No public API is recorded for Bioscript Group.

What industry is Bioscript Group in?

Bioscript Group's product category is Medical Communications & Strategy Consulting. Its primary akta.pro industry code is HLAGAGAL, GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 54169 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Sovereign Capital PartnersBioscript strengthens evidence-generation capability with acquisition of TriduciveBioscript Group completed the acquisition of Triducive Partners, a consultancy that helps pharmaceutical companies gather expert clinical opinion. Triducive, founded in 2009, will integrate into Bioscript's Data and Insights division, with co-founders Tim Warren and Nick Williams remaining. This is the fifth acquisition since Sovereign Capital Partners invested in 2021.BioscriptgroupBioscript Group Announces Acquisition of TriduciveBioscript Group acquired Triducive Partners, a consultancy specializing in consensus-driven evidence generation and structured insight development. Triducive will join Bioscript's Data Insights division, with co-founders Tim Warren and Nick Williams continuing to lead the team. The integration aims to enhance insight generation and translate it into effective communication strategies.ProlificnorthMacclesfield’s Bioscript Group acquires Enzyme CommunicationsBioscript Group has acquired Enzyme Communications, a science communication expert specializing in oncology and rare diseases. This acquisition integrates Enzyme's strategic planning and scientific storytelling capabilities into Bioscript's medical communications division to enhance its service offerings. The Enzyme team will continue to be led by co-founders Neil Kumar and Adam Goodband.PharmaLiveBioscript Group acquires Enzyme Communications to bolster its medical writing, scientific content creation and storytelling capabilitiesBioscript Group has acquired Enzyme Communications, a science communication expert, to enhance its capabilities in medical writing and scientific storytelling. This acquisition adds specialist knowledge in oncology and rare diseases to Bioscript Group's portfolio while allowing Enzyme Communications to scale its services under new leadership. The deal is expected to strengthen the combined entity's offerings to pharmaceutical clients across the life sciences sector.PharmiWeb.comBioscript Group acquires Enzyme Communications to bolster its medical writing, scientific content creation and storytelling capabilitiesBioscript Group announced the acquisition of Enzyme Communications on April 30, 2024, aimed at enhancing its capabilities in medical writing and scientific storytelling. This acquisition adds significant expertise in oncology and rare diseases, aligning with Bioscript Group's goal to lead in scientific communications for the life sciences sector. The integration of Enzyme Communications is expected to bolster service offerings and facilitate growth opportunities within the group.